Back

Antibody Responses to SARS-CoV-2 Vaccine in Nursing Home Residents Support a Bi-Annual Update Schedule

Paxitzis, A. N.; Oyebanji, O. A.; Olagunju, O. J.; Keresztesy, D.; Payne, M.; Ragavapuram, V.; Sundheimer, N.; See, E.; Wilk, D.; Cao, Y.; Abul, Y.; Nugent, C.; Dickerson, E.; Wallace, T.; Holland, L.; Nanda, A.; Pfeifer, W. M.; Balazs, A. B.; King, C. L.; Gravenstein, S.; Canaday, D. H.; Wilson, B. M.; Bosch, J.

2025-01-16 geriatric medicine
10.1101/2025.01.09.25320262 medRxiv
Show abstract

BackgroundThe COVID-19 pandemic has greatly affected nursing home residents (NHRs), a vulnerable group with high rates of illness and death. While vaccination is essential for reducing infections and severe outcomes in the short term, it is important to understand how long antibody levels and neutralizing activity last. This understanding will help us create effective public health strategies for the long term. According to current CDC guidelines, individuals over the age of 65 should receive a booster dose six months after their previous vaccination. MethodsThis observational retrospective cohort study analyzed post-vaccination serum from samples with up to 400 days of follow-up from 697 NHRs and 127 healthcare workers (HCWs) across Northeast Ohio and Rhode Island. Analyses were conducted to model decay rates of both neutralizing and binding antibody titers and the impact of previous exposures to SARS-CoV-2 on these decay rates. ResultsResults indicate that NHRs show Wuhan and Omicron BA.4/5 neutralizing and binding antibody titers diminish significantly from 2 weeks to 12 months post-vaccination. NHRs with prior infection show higher peak antibody titers and slower decay than those naive to infection. Antibody levels after vaccination for infection-naive NHR residents lagged HCW and NHR with prior infection, but then decayed at a similar rate. ConclusionThe immunologic findings in this cohort of NHR are in line with the existing real-world clinical effectiveness data in older individuals and support the CDC recommendation of a bi-annual vaccination to reduce severe COVID-19 outcomes in persons age 65 and older.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 10%
18.5%
2
Journal of the American Medical Directors Association
13 papers in training set
Top 0.1%
17.4%
3
Journal of the American Geriatrics Society
12 papers in training set
Top 0.1%
14.6%
50% of probability mass above
4
Age and Ageing
27 papers in training set
Top 0.1%
6.3%
5
BMC Geriatrics
15 papers in training set
Top 0.1%
4.3%
6
BMJ Open
554 papers in training set
Top 5%
3.9%
7
Aging
69 papers in training set
Top 0.7%
3.6%
8
Frontiers in Public Health
140 papers in training set
Top 2%
3.6%
9
Cureus
67 papers in training set
Top 1%
3.1%
10
eClinicalMedicine
55 papers in training set
Top 0.3%
2.3%
11
BMC Medicine
163 papers in training set
Top 3%
2.1%
12
International Journal of Environmental Research and Public Health
124 papers in training set
Top 3%
2.1%
13
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.3%
1.9%
14
Healthcare
16 papers in training set
Top 1%
1.2%
15
Vaccines
196 papers in training set
Top 2%
1.1%
16
Frontiers in Medicine
113 papers in training set
Top 5%
0.9%
17
Frontiers in Physiology
93 papers in training set
Top 5%
0.9%
18
Archives of Public Health
12 papers in training set
Top 0.6%
0.8%
19
Alzheimer's & Dementia
143 papers in training set
Top 3%
0.8%
20
Frontiers in Aging
10 papers in training set
Top 0.4%
0.8%
21
The Journals of Gerontology: Series A
25 papers in training set
Top 0.9%
0.7%
22
The Lancet Healthy Longevity
11 papers in training set
Top 0.2%
0.7%